Eko Health, a company applying artificial intelligence (AI) for early detection of heart and lung diseases, announced FDA clearance for its Low EF detection AI. U.S. healthcare providers can now detect Low EF, a key heart failure indicator, in 15 seconds using an Eko stethoscope during a routine physical examination.
"The ability to identify a hidden, potentially life-threatening heart condition using a tool that primary care and subspecialist clinicians are familiar with – the stethoscope – can help us prevent hospitalizations and adverse events," said Dr. Paul Friedman, Chair of the Department of Cardiovascular Medicine at Mayo Clinic in Rochester. "Importantly, since a stethoscope is small and portable, this technology can be used in urban and remote locations, and hopefully help address care in underserved areas."
The Low EF AI will be added to Eko's SENSORA Cardiac Early Detection Platform, the latest advancement to the platform which already features FDA-cleared algorithms to identify AFib and structural heart murmurs, often an indicator of valvular heart disease. When Low EF is detected in a primary care exam with SENSORA, access to life-extending treatment can be expedited with a referral to the cardiology department for thorough diagnostic testing and treatment evaluation.
"The stethoscope, the most recognizable symbol of healthcare, touches the lives of an estimated one billion people around the globe every year," said Connor Landgraf, co-founder & CEO of Eko Health. "With Eko's Low EF AI, we've transformed the icon of medicine into an AI-powered heart failure early detection tool that can help improve access to care for millions of patients, at a fraction of the time and cost of echocardiography. It's been a privilege to work alongside Mayo Clinic in this groundbreaking endeavor."
